European Medicines Agency to Review Novo Nordisk's Ozempic Due to Eye Disease Risk Concerns

The European Medicines Agency (EMA) is set to investigate concerns regarding Novo Nordisk's Ozempic due to potential risks associated with non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye disease causing sudden vision loss. This decision follows an appeal from the Danish Medicines Agency, which cited two new studies suggesting a possible link between Ozempic's active ingredient, semaglutide, and NAION[1][2]. These studies include data from extensive patient cohorts in Denmark and Norway, raising sufficient concern to warrant a formal review by the European Pharmacovigilance Risk Assessment Committee. Despite these findings, NAION remains rare, and no definitive link has been confirmed, although the reports have sparked a significant review process[1][3].